Unitree Robotics' Shanghai debut compressed years of expected robot adoption into one trading session. The stock was sold in the initial public offering at 150.80 yuan, opened at 1,100 yuan and closed at 845 yuan, according to the Associated Press. The 460% closing gain was genuine for a buyer allocated IPO shares, but it did not put 460% more cash into Unitree's factories or research budget.
That distinction is the starting point for valuation. Unitree's financial disclosures show unusually rapid commercialization and positive cash generation. The debut price nevertheless asks investors to value a manufacturing business on a much larger future market than the one visible in current revenue.
The company raised at 150.80 yuan, not 845
Unitree issued about 40.45 million new shares, equal to 10% of its enlarged share capital, at the offer price. The Shanghai Stock Exchange's listing coverage put gross proceeds near 6.1 billion yuan. Yicai reported net proceeds of about 5.9 billion yuan after costs. That capital can finance robot models, new products and manufacturing capacity.
Trading above the offer price changes who owns the shares and the market value assigned to them; it does not retroactively increase IPO proceeds. A company can later exploit a higher price by issuing more stock, using shares in acquisitions or improving employee compensation economics, but those are possible future transactions. The day-one premium itself accrued to shareholders.
A thin listed slice set the price for the whole company
Because the new shares represented 10% of post-offer capital, the offer implied roughly 404.5 million total shares. At the 845-yuan close, that share count produced a market capitalization near 341.7 billion yuan, matching Yicai's reported figure. A relatively small tradeable slice therefore established a price for all shares, including those that were not changing hands.
This is normal market mechanics, but scarcity can amplify the first signal. Mainland investors gained their first listed pure-play humanoid-robot manufacturer while only a limited portion of the equity entered the market. The result measures demand for available shares as well as an assessment of future cash flows.
For scale, Unitree's prospectus reported 1.708 billion yuan of 2025 revenue. The closing market value was therefore about 200 times that revenue. This trailing ratio is not a forecast or a verdict, but it shows how little of the valuation can be explained by the latest sales base alone. Investors are underwriting a transition from fast unit growth to a much larger installed base.
Humanoids became the revenue engine before the listing
The business is not merely a demonstration reel. Prospectus tables show main-business revenue rising from 121.2 million yuan in 2022 to 387.3 million yuan in 2024, then reaching 1.155 billion yuan in the first nine months of 2025. Humanoid robots moved from 1.88% of that revenue in 2023 to 27.60% in 2024 and 51.53% in the first nine months of 2025. Quadruped robots supplied another 42.25% in that latest period.
Volume mattered. Unitree sold 17,946 quadruped robots in the first nine months of 2025, while the average selling price fell to 27,200 yuan from 38,300 yuan in 2023. That combination suggests manufacturing scale and lower pricing broadened demand. Main-business gross margin also rose to 59.45% in the nine-month period from 44.22% in 2023, although product mix and later competition can change it.
The prospectus reported 672.1 million yuan of operating cash flow for full-year 2025 and 600.1 million yuan of profit excluding non-recurring items. Reported net profit was lower because a one-time share-based payment expense reduced it. These are stronger foundations than a pre-revenue robotics story, but they remain small beside the value assigned at the close.
Deployment evidence must replace debut scarcity
The central uncertainty is what customers do with the robots after delivery. AP noted that many humanoids across the industry are still used for demonstrations, performances and research rather than repeatable commercial tasks. Shipping a unit proves production and demand; it does not by itself prove that the buyer earns an attractive return or orders a fleet.
The bullish counterargument is substantial. Revenue expanded more than fourfold in 2025, humanoids became the largest product category and cash flow was positive. A trailing multiple can be misleading when a market is forming quickly. Yet a high multiple also leaves less room for slower adoption, falling prices, new competitors or larger service costs.
Evidence that would strengthen the valuation includes repeat orders from industrial customers, deployment hours, failure and maintenance rates, software or service revenue, and margins sustained after price reductions. A larger free float and several quarters of trading would also show whether the debut premium reflected durable conviction or temporary scarcity. Unitree has already proved it can sell robots; the public market now requires proof that customers can deploy them economically.